Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 296

1.

Neutrophils suppress tumor-infiltrating T cells in colon cancer via matrix metalloproteinase-mediated activation of TGFβ.

Germann M, Zangger N, Sauvain MO, Sempoux C, Bowler AD, Wirapati P, Kandalaft LE, Delorenzi M, Tejpar S, Coukos G, Radtke F.

EMBO Mol Med. 2019 Dec 2:e10681. doi: 10.15252/emmm.201910681. [Epub ahead of print]

2.

A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma.

Sarivalasis A, Boudousquié C, Balint K, Stevenson BJ, Gannon PO, Iancu EM, Rossier L, Martin Lluesma S, Mathevet P, Sempoux C, Coukos G, Dafni U, Harari A, Bassani-Sternberg M, Kandalaft LE.

J Transl Med. 2019 Nov 26;17(1):391. doi: 10.1186/s12967-019-02133-w.

3.

Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment.

Newey A, Griffiths B, Michaux J, Pak HS, Stevenson BJ, Woolston A, Semiannikova M, Spain G, Barber LJ, Matthews N, Rao S, Watkins D, Chau I, Coukos G, Racle J, Gfeller D, Starling N, Cunningham D, Bassani-Sternberg M, Gerlinger M.

J Immunother Cancer. 2019 Nov 18;7(1):309. doi: 10.1186/s40425-019-0769-8.

4.

CD8 Binding of MHC-Peptide Complexes in cis or trans Regulates CD8+ T-cell Responses.

Liu Y, Cuendet MA, Goffin L, Šachl R, Cebecauer M, Cariolato L, Guillaume P, Reichenbach P, Irving M, Coukos G, Luescher IF.

J Mol Biol. 2019 Nov 5. pii: S0022-2836(19)30615-1. doi: 10.1016/j.jmb.2019.10.019. [Epub ahead of print]

5.

Gender Medicine and Oncology: Report and consensus of an ESMO Workshop.

Wagner AD, Oertelt-Prigione S, Adjei A, Buclin T, Cristina V, Csajka C, Coukos G, Dafni U, Dotto GP, Ducreux M, Fellay J, Haanen J, Hocquelet A, Klinge I, Lemmens V, Letsch A, Mauer M, Moehler M, Peters S, Özdemir BC.

Ann Oncol. 2019 Oct 15. pii: mdz414. doi: 10.1093/annonc/mdz414. [Epub ahead of print]

PMID:
31613312
6.

Robust prediction of HLA class II epitopes by deep motif deconvolution of immunopeptidomes.

Racle J, Michaux J, Rockinger GA, Arnaud M, Bobisse S, Chong C, Guillaume P, Coukos G, Harari A, Jandus C, Bassani-Sternberg M, Gfeller D.

Nat Biotechnol. 2019 Nov;37(11):1283-1286. doi: 10.1038/s41587-019-0289-6. Epub 2019 Oct 14.

PMID:
31611696
7.

Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8+ T cells.

Mastelic-Gavillet B, Navarro Rodrigo B, Décombaz L, Wang H, Ercolano G, Ahmed R, Lozano LE, Ianaro A, Derré L, Valerio M, Tawadros T, Jichlinski P, Nguyen-Ngoc T, Speiser DE, Verdeil G, Gestermann N, Dormond O, Kandalaft L, Coukos G, Jandus C, Ménétrier-Caux C, Caux C, Ho PC, Romero P, Harari A, Vigano S.

J Immunother Cancer. 2019 Oct 10;7(1):257. doi: 10.1186/s40425-019-0719-5.

8.

Efficacy of Adoptive Therapy with Tumor-infiltrating Lymphocytes and Recombinant Interleukin-2 in Advanced Cutaneous Melanoma: A Systematic Review and Meta-analysis.

Dafni U, Michielin O, Lluesma SM, Tsourti Z, Polydoropoulou V, Karlis D, Besser MJ, Haanen J, Svane IM, Ohashi PS, Kammula US, Orcurto A, Zimmermann S, Trueb L, Klebanoff CA, Lotze MT, Kandalaft LE, Coukos G.

Ann Oncol. 2019 Sep 30. pii: mdz398. doi: 10.1093/annonc/mdz398. [Epub ahead of print]

PMID:
31566658
9.

Integrating SpyCatcher/SpyTag covalent fusion technology into phage display workflows for rapid antibody discovery.

Fierle JK, Abram-Saliba J, Brioschi M, deTiani M, Coukos G, Dunn SM.

Sci Rep. 2019 Sep 6;9(1):12815. doi: 10.1038/s41598-019-49233-7.

10.

A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma-A Proof of Antigen Discovery Feasibility in Three Patients.

Bassani-Sternberg M, Digklia A, Huber F, Wagner D, Sempoux C, Stevenson BJ, Thierry AC, Michaux J, Pak H, Racle J, Boudousquie C, Balint K, Coukos G, Gfeller D, Martin Lluesma S, Harari A, Demartines N, Kandalaft LE.

Front Immunol. 2019 Aug 8;10:1832. doi: 10.3389/fimmu.2019.01832. eCollection 2019.

11.

Immunotherapy in Ovarian Cancer: Are We There Yet?

Kandalaft LE, Odunsi K, Coukos G.

J Clin Oncol. 2019 Sep 20;37(27):2460-2471. doi: 10.1200/JCO.19.00508. Epub 2019 Aug 12. No abstract available.

PMID:
31403857
12.

Rational combinations of immunotherapy with radiotherapy in ovarian cancer.

Herrera FG, Irving M, Kandalaft LE, Coukos G.

Lancet Oncol. 2019 Aug;20(8):e417-e433. doi: 10.1016/S1470-2045(19)30401-2. Epub 2019 Jul 29. Review. Erratum in: Lancet Oncol. 2019 Sep;20(9):e468.

PMID:
31364594
13.

Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function.

Vigano S, Alatzoglou D, Irving M, Ménétrier-Caux C, Caux C, Romero P, Coukos G.

Front Immunol. 2019 Jun 6;10:925. doi: 10.3389/fimmu.2019.00925. eCollection 2019. Review.

14.

Mass spectrometry driven exploration reveals nuances of neoepitope-driven tumor rejection.

Ebrahimi-Nik H, Michaux J, Corwin WL, Keller GL, Shcheglova T, Pak H, Coukos G, Baker BM, Mandoiu II, Bassani-Sternberg M, Srivastava PK.

JCI Insight. 2019 Jun 20;5. pii: 129152. doi: 10.1172/jci.insight.129152.

15.

18F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer.

Jreige M, Letovanec I, Chaba K, Renaud S, Rusakiewicz S, Cristina V, Peters S, Krueger T, de Leval L, Kandalaft LE, Nicod-Lalonde M, Romero P, Prior JO, Coukos G, Schaefer N.

Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1859-1868. doi: 10.1007/s00259-019-04348-x. Epub 2019 Jun 18.

PMID:
31214790
16.

Internal radiation dosimetry of a 152Tb-labeled antibody in tumor-bearing mice.

Cicone F, Gnesin S, Denoël T, Stora T, van der Meulen NP, Müller C, Vermeulen C, Benešová M, Köster U, Johnston K, Amato E, Auditore L, Coukos G, Stabin M, Schaefer N, Viertl D, Prior JO.

EJNMMI Res. 2019 Jun 11;9(1):53. doi: 10.1186/s13550-019-0524-7.

17.

Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors.

Dangaj D, Bruand M, Grimm AJ, Ronet C, Barras D, Duttagupta PA, Lanitis E, Duraiswamy J, Tanyi JL, Benencia F, Conejo-Garcia J, Ramay HR, Montone KT, Powell DJ Jr, Gimotty PA, Facciabene A, Jackson DG, Weber JS, Rodig SJ, Hodi SF, Kandalaft LE, Irving M, Zhang L, Foukas P, Rusakiewicz S, Delorenzi M, Coukos G.

Cancer Cell. 2019 Jun 10;35(6):885-900.e10. doi: 10.1016/j.ccell.2019.05.004.

PMID:
31185212
18.

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.

Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A, Guex-Crosier Y, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, Thompson JA, Obeid M.

Nat Rev Clin Oncol. 2019 Sep;16(9):563-580. doi: 10.1038/s41571-019-0218-0. Review.

PMID:
31092901
19.

[Side effects of immune checkpoint inhibitors: diagnosis and management].

Perrinjaquet C, Zaher M, Ferraro DA, Comte D, Trueb L, Zimmermann S, Coukos G, Orcurto A.

Rev Med Suisse. 2019 May 15;15(651):1010-1016. French.

PMID:
31091034
20.

High-throughput Screening of Human Tumor Antigen-specific CD4 T Cells, Including Neoantigen-reactive T Cells.

Costa-Nunes C, Cachot A, Bobisse S, Arnaud M, Genolet R, Baumgaertner P, Speiser DE, Sousa Alves PM, Sandoval F, Adotévi O, Reith W, Protti MP, Coukos G, Harari A, Romero P, Jandus C.

Clin Cancer Res. 2019 Jul 15;25(14):4320-4331. doi: 10.1158/1078-0432.CCR-18-1356. Epub 2019 Apr 23.

PMID:
31015344
21.

The clinical application of cancer immunotherapy based on naturally circulating dendritic cells.

Bol KF, Schreibelt G, Rabold K, Wculek SK, Schwarze JK, Dzionek A, Teijeira A, Kandalaft LE, Romero P, Coukos G, Neyns B, Sancho D, Melero I, de Vries IJM.

J Immunother Cancer. 2019 Apr 18;7(1):109. doi: 10.1186/s40425-019-0580-6. Review.

22.

Going Beyond the Sequences: TCR Binding Patterns at the Service of Cancer Detection.

Zoete V, Coukos G.

Cancer Res. 2019 Apr 1;79(7):1299-1301. doi: 10.1158/0008-5472.CAN-19-0225.

PMID:
30936076
23.

Correction: Tumour-reactive T cell subsets in the microenvironment of ovarian cancer.

Westergaard MCW, Andersen R, Chong C, Kjeldsen JW, Pedersen M, Friese C, Hasselager T, Lajer H, Coukos G, Bassani-Sternberg M, Donia M, Svane IM.

Br J Cancer. 2019 Apr;120(8):870. doi: 10.1038/s41416-019-0425-6.

24.

Computational KIR copy number discovery reveals interaction between inhibitory receptor burden and survival.

Pyke RM, Genolet R, Harari A, Coukos G, Gfeller D, Carter H.

Pac Symp Biocomput. 2019;24:148-159.

25.

The NAD-Booster Nicotinamide Riboside Potently Stimulates Hematopoiesis through Increased Mitochondrial Clearance.

Vannini N, Campos V, Girotra M, Trachsel V, Rojas-Sutterlin S, Tratwal J, Ragusa S, Stefanidis E, Ryu D, Rainer PY, Nikitin G, Giger S, Li TY, Semilietof A, Oggier A, Yersin Y, Tauzin L, Pirinen E, Cheng WC, Ratajczak J, Canto C, Ehrbar M, Sizzano F, Petrova TV, Vanhecke D, Zhang L, Romero P, Nahimana A, Cherix S, Duchosal MA, Ho PC, Deplancke B, Coukos G, Auwerx J, Lutolf MP, Naveiras O.

Cell Stem Cell. 2019 Mar 7;24(3):405-418.e7. doi: 10.1016/j.stem.2019.02.012.

PMID:
30849366
26.

Tumor Landscapes: β-Catenin Drives Immune Desertification.

Dangaj D, Barras D, Coukos G.

Clin Cancer Res. 2019 May 15;25(10):2943-2945. doi: 10.1158/1078-0432.CCR-19-0188. Epub 2019 Mar 5.

PMID:
30837277
27.

Tumour-reactive T cell subsets in the microenvironment of ovarian cancer.

Westergaard MCW, Andersen R, Chong C, Kjeldsen JW, Pedersen M, Friese C, Hasselager T, Lajer H, Coukos G, Bassani-Sternberg M, Donia M, Svane IM.

Br J Cancer. 2019 Feb;120(4):424-434. doi: 10.1038/s41416-019-0384-y. Epub 2019 Feb 5. Erratum in: Br J Cancer. 2019 Apr;120(8):870.

PMID:
30718808
28.

Safety and Tolerability of Adoptive Cell Therapy in Cancer.

Wolf B, Zimmermann S, Arber C, Irving M, Trueb L, Coukos G.

Drug Saf. 2019 Feb;42(2):315-334. doi: 10.1007/s40264-018-0779-3. Review.

PMID:
30649750
29.

[Recent advances and future directions in CAR-T cell therapy in pediatric oncology].

Ceppi F, Renella R, Diezi M, Ansari M, Duchosal MA, Arber C, Kandalaft L, Coukos G, Beck-Popovic M.

Rev Med Suisse. 2019 Jan 9;15(N° 632-633):85-91. Review. French.

PMID:
30629377
30.

New therapeutic perspectives to manage refractory immune checkpoint-related toxicities.

Martins F, Sykiotis GP, Maillard M, Fraga M, Ribi C, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, Thompson JA, Obeid M.

Lancet Oncol. 2019 Jan;20(1):e54-e64. doi: 10.1016/S1470-2045(18)30828-3.

PMID:
30614479
31.

A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy.

Horisberger A, La Rosa S, Zurcher JP, Zimmermann S, Spertini F, Coukos G, Obeid M.

J Immunother Cancer. 2018 Dec 27;6(1):156. doi: 10.1186/s40425-018-0481-0.

32.

Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy.

Maio M, Coukos G, Ferrone S, Fox BA, Fridman WH, Garcia PL, Lahn M, Provendier O, Russo V, Rüttinger D, Shalabi A, Trajanoski Z, Viallet J, Wolchok JD, Ibrahim R.

Cancer Immunol Immunother. 2019 Jan;68(1):1-9. doi: 10.1007/s00262-018-2285-y. Epub 2018 Dec 18.

PMID:
30564889
33.

The Length Distribution and Multiple Specificity of Naturally Presented HLA-I Ligands.

Gfeller D, Guillaume P, Michaux J, Pak HS, Daniel RT, Racle J, Coukos G, Bassani-Sternberg M.

J Immunol. 2018 Dec 15;201(12):3705-3716. doi: 10.4049/jimmunol.1800914. Epub 2018 Nov 14.

PMID:
30429286
34.

A severe case of neuro-Sjögren's syndrome induced by pembrolizumab.

Ghosn J, Vicino A, Michielin O, Coukos G, Kuntzer T, Obeid M.

J Immunother Cancer. 2018 Oct 22;6(1):110. doi: 10.1186/s40425-018-0429-4.

35.

Two-Dimensional Label-Free Affinity Analysis of Tumor-Specific CD8 T Cells with a Biomimetic Plasmonic Sensor.

Soler M, Li X, John-Herpin A, Schmidt J, Coukos G, Altug H.

ACS Sens. 2018 Nov 26;3(11):2286-2295. doi: 10.1021/acssensors.8b00523. Epub 2018 Oct 19.

PMID:
30339020
36.

50-Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a/b Trial.

Herrera FG, Valerio M, Berthold D, Tawadros T, Meuwly JY, Vallet V, Baumgartner P, Thierry AC, De Bari B, Jichlinski P, Kandalaft L, Coukos G, Harari A, Bourhis J.

Int J Radiat Oncol Biol Phys. 2019 Feb 1;103(2):320-334. doi: 10.1016/j.ijrobp.2018.09.023. Epub 2018 Sep 27.

37.

Correction to: CART cells are prone to Fas- and DR5-mediated cell death.

Tschumi BO, Dumauthioz N, Marti B, Zhang L, Lanitis E, Irving M, Schneider P, Mach JP, Coukos G, Romero P, Donda A.

J Immunother Cancer. 2018 Sep 25;6(1):92. doi: 10.1186/s40425-018-0410-2.

38.

Cancer Immunotherapy: A Simple Guide for Interventional Radiologists of New Therapeutic Approaches.

Digklia A, Duran R, Homicsko K, Kandalaft LE, Hocquelet A, Orcurto A, Coukos G, Denys A.

Cardiovasc Intervent Radiol. 2019 Sep;42(9):1221-1229. doi: 10.1007/s00270-018-2074-1. Epub 2018 Sep 12.

PMID:
30209564
39.

Estimating the Contribution of Proteasomal Spliced Peptides to the HLA-I Ligandome.

Mylonas R, Beer I, Iseli C, Chong C, Pak HS, Gfeller D, Coukos G, Xenarios I, Müller M, Bassani-Sternberg M.

Mol Cell Proteomics. 2018 Dec;17(12):2347-2357. doi: 10.1074/mcp.RA118.000877. Epub 2018 Aug 31.

40.

CART cells are prone to Fas- and DR5-mediated cell death.

Tschumi BO, Dumauthioz N, Marti B, Zhang L, Lanitis E, Irving M, Schneider P, Mach JP, Coukos G, Romero P, Donda A.

J Immunother Cancer. 2018 Jul 13;6(1):71. doi: 10.1186/s40425-018-0385-z. Erratum in: J Immunother Cancer. 2018 Sep 25;6(1):92.

41.

Current Opinion and Knowledge on Peritoneal Carcinomatosis: A Survey among a Swiss Oncology Network.

Grass F, Martin D, Montemurro M, Mathevet P, Wolfer A, Coukos G, Demartines N, Hübner M.

Chemotherapy. 2018;63(3):143-147. doi: 10.1159/000488774. Epub 2018 Jun 13.

PMID:
29898438
42.

Label-Free Optofluidic Nanobiosensor Enables Real-Time Analysis of Single-Cell Cytokine Secretion.

Li X, Soler M, Szydzik C, Khoshmanesh K, Schmidt J, Coukos G, Mitchell A, Altug H.

Small. 2018 Jun;14(26):e1800698. doi: 10.1002/smll.201800698. Epub 2018 May 28.

PMID:
29806234
43.

Consensus guidelines for the use and interpretation of angiogenesis assays.

Nowak-Sliwinska P, Alitalo K, Allen E, Anisimov A, Aplin AC, Auerbach R, Augustin HG, Bates DO, van Beijnum JR, Bender RHF, Bergers G, Bikfalvi A, Bischoff J, Böck BC, Brooks PC, Bussolino F, Cakir B, Carmeliet P, Castranova D, Cimpean AM, Cleaver O, Coukos G, Davis GE, De Palma M, Dimberg A, Dings RPM, Djonov V, Dudley AC, Dufton NP, Fendt SM, Ferrara N, Fruttiger M, Fukumura D, Ghesquière B, Gong Y, Griffin RJ, Harris AL, Hughes CCW, Hultgren NW, Iruela-Arispe ML, Irving M, Jain RK, Kalluri R, Kalucka J, Kerbel RS, Kitajewski J, Klaassen I, Kleinmann HK, Koolwijk P, Kuczynski E, Kwak BR, Marien K, Melero-Martin JM, Munn LL, Nicosia RF, Noel A, Nurro J, Olsson AK, Petrova TV, Pietras K, Pili R, Pollard JW, Post MJ, Quax PHA, Rabinovich GA, Raica M, Randi AM, Ribatti D, Ruegg C, Schlingemann RO, Schulte-Merker S, Smith LEH, Song JW, Stacker SA, Stalin J, Stratman AN, Van de Velde M, van Hinsbergh VWM, Vermeulen PB, Waltenberger J, Weinstein BM, Xin H, Yetkin-Arik B, Yla-Herttuala S, Yoder MC, Griffioen AW.

Angiogenesis. 2018 Aug;21(3):425-532. doi: 10.1007/s10456-018-9613-x. Review.

44.

The C-terminal extension landscape of naturally presented HLA-I ligands.

Guillaume P, Picaud S, Baumgaertner P, Montandon N, Schmidt J, Speiser DE, Coukos G, Bassani-Sternberg M, Filippakopoulos P, Gfeller D.

Proc Natl Acad Sci U S A. 2018 May 15;115(20):5083-5088. doi: 10.1073/pnas.1717277115. Epub 2018 Apr 30.

45.

Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.

Tanyi JL, Bobisse S, Ophir E, Tuyaerts S, Roberti A, Genolet R, Baumgartner P, Stevenson BJ, Iseli C, Dangaj D, Czerniecki B, Semilietof A, Racle J, Michel A, Xenarios I, Chiang C, Monos DS, Torigian DA, Nisenbaum HL, Michielin O, June CH, Levine BL, Powell DJ Jr, Gfeller D, Mick R, Dafni U, Zoete V, Harari A, Coukos G, Kandalaft LE.

Sci Transl Med. 2018 Apr 11;10(436). pii: eaao5931. doi: 10.1126/scitranslmed.aao5931.

PMID:
29643231
46.

T cell-induced CSF1 promotes melanoma resistance to PD1 blockade.

Neubert NJ, Schmittnaegel M, Bordry N, Nassiri S, Wald N, Martignier C, Tillé L, Homicsko K, Damsky W, Maby-El Hajjami H, Klaman I, Danenberg E, Ioannidou K, Kandalaft L, Coukos G, Hoves S, Ries CH, Fuertes Marraco SA, Foukas PG, De Palma M, Speiser DE.

Sci Transl Med. 2018 Apr 11;10(436). pii: eaan3311. doi: 10.1126/scitranslmed.aan3311.

47.

Sensitive and frequent identification of high avidity neo-epitope specific CD8 + T cells in immunotherapy-naive ovarian cancer.

Bobisse S, Genolet R, Roberti A, Tanyi JL, Racle J, Stevenson BJ, Iseli C, Michel A, Le Bitoux MA, Guillaume P, Schmidt J, Bianchi V, Dangaj D, Fenwick C, Derré L, Xenarios I, Michielin O, Romero P, Monos DS, Zoete V, Gfeller D, Kandalaft LE, Coukos G, Harari A.

Nat Commun. 2018 Mar 15;9(1):1092. doi: 10.1038/s41467-018-03301-0.

48.

Correction to: Characterization of the first fully human anti-TEM1 scFv in models of solid tumor imaging and immunotoxin-based therapy.

Yuan X, Yang M, Chen X, Zhang X, Sukhadia S, Musolino N, Bao H, Chen T, Xu C, Wang Q, Santoro S, Ricklin D, Hu J, Lin R, Yang W, Li Z, Qin W, Zhao A, Scholler N, Coukos G.

Cancer Immunol Immunother. 2018 Feb;67(2):329-339. doi: 10.1007/s00262-017-2101-0.

PMID:
29313073
49.

Tumour endothelial marker 1/endosialin-mediated targeting of human sarcoma.

Guo Y, Hu J, Wang Y, Peng X, Min J, Wang J, Matthaiou E, Cheng Y, Sun K, Tong X, Fan Y, Zhang PJ, Kandalaft LE, Irving M, Coukos G, Li C.

Eur J Cancer. 2018 Feb;90:111-121. doi: 10.1016/j.ejca.2017.10.035. Epub 2018 Jan 4.

PMID:
29304474
50.

Immune-related adverse events of immune checkpoint inhibitors and the impact of sex-what we know and what we need to learn.

Özdemir BC, Coukos G, Wagner AD.

Ann Oncol. 2018 Apr 1;29(4):1067. doi: 10.1093/annonc/mdx818. No abstract available.

PMID:
29300807

Supplemental Content

Loading ...
Support Center